Marshall Wace’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Marshall Wace’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-62,506	Closed	-$290K	–	3429
2022 Q3	$290K	Buy	62,506 +14	+0%	+$10	﹤0.01%	2964
2022 Q2	$314K	Hold	62,492	–	–	﹤0.01%	3010
2022 Q1	$444K	Hold	62,492	–	–	﹤0.01%	2828
2021 Q4	$610K	Hold	62,492	–	–	﹤0.01%	2701
2021 Q3	$620K	Hold	62,492	–	–	﹤0.01%	2289
2021 Q2	$621K	Hold	62,492	–	–	﹤0.01%	2038
2021 Q1	$623K	Hold	62,492	–	–	﹤0.01%	1856
2020 Q4	$675K	Buy	+62,492	New	+$108K	﹤0.01%	1364

Other funds holding STLNW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

DCM

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Marshall Wace's STLNW Position: Q4 2020 in Review

Marshall Wace sold out of Starling Oncology, Inc. Warrant (STLNW) in Q4 2020, closing a stake of 62,492 shares — an estimated $108K sold.

Marshall Wace first reported a position in STLNW in Q3 2020 and held it in 1 quarter. The position peaked at $106K in Q3 2020. 25 funds tracked by Wall St. Rank hold STLNW as of Q4 2020.

Marshall Wace reported no remaining Starling Oncology, Inc. Warrant position as of Q4 2020 after selling out during the quarter.
Marshall Wace sold 62,492 Starling Oncology, Inc. Warrant shares in Q4 2020, an estimated $108K.
Marshall Wace first reported a position in Starling Oncology, Inc. Warrant in Q3 2020 and held it in 1 quarter.
Marshall Wace's Starling Oncology, Inc. Warrant position peaked at $106K in Q3 2020.
25 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q4 2020.

Based on Marshall Wace's 13F filing for Q4 2020, filed 16 Feb 2021.